Hummelstown, PA (December 9, 2013) – Oncoceutics, Inc. announced that a research team led by Michael Andreeff, MD, PhD, at the University of Texas MD Anderson Cancer Center, has presented data on ONC201, the lead drug compound developed by the company, at the annual meeting of the American Society of Hematology (ASH) in New Orleans.
Hummelstown, PA (October 3, 2013) – Oncoceutics, Inc. announced the closing of an investment by Calvert Research, LLC into the company that will be used to advance ONC201 to an IND filing. Oncoceutics is developing ONC201, an orally active small molecule with a compelling efficacy and safety profile in preclinical studies against cancer cells (in
Hummelstown, PA (June 24, 2013) – Oncoceutics, Inc. announced that Kuwait University Medical School Professor Fahd Al-Mulla has joined the company’s scientific advisory board. Dr. Al-Mulla FRCP is University Professor of molecular Pathology at Kuwait University Medical School and is the director of genomic medicine at Genatak, Kuwait. Prior to joining Genatak, Dr. Al-Mulla established
Business Development